Related Experiment Video
Updated: Jan 11, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Advancements in Fibrinogen Replacement for Major Bleeding: Insights From Case Series
David S Shapiro1, Daniel Katz2, John J Kowalczyk3
1Department of Surgery, University of Connecticut School of Medicine, Farmington, USA.
Timely fibrinogen replacement is crucial for managing major bleeding in cardiac, obstetric, and trauma patients. Using fibrinogen concentrate or pathogen-reduced cryoprecipitate can rapidly restore clot stability and improve outcomes.
Area of Science:
- Hematology
- Critical Care Medicine
- Anesthesiology
Background:
- Acquired fibrinogen deficiency (AFD) impairs hemostasis during major bleeding.
- Clot stability is compromised by low fibrinogen levels.
- Effective management of critical bleeding requires addressing AFD.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

